SEC Comment Letter 0000000000-25-002426 to Edesa Biotech, Inc. (EDSA)

Edesa Biotech, Inc.
Date: March 4, 2025 · CIK: 0001540159 · Accession: 0000000000-25-002426

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37619

Date

March 4, 2025

Author

Stephen Lemieux

Form

UPLOAD

Company

Edesa Biotech, Inc.

Letter

March 4, 2025 Stephen Lemieux Chief Financial Officer Edesa Biotech, Inc. 100 Spy Court Markum, ON L3R 5H6 Canada Re:Edesa Biotech, Inc. Form 10-K for Fiscal Year Ended September 30, 2024 File No. 001-37619 Dear Stephen Lemieux: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

March 4, 2025
Stephen Lemieux
Chief Financial Officer
Edesa Biotech, Inc.
100 Spy Court
Markum, ON L3R 5H6
Canada
Re:Edesa Biotech, Inc.
Form 10-K for Fiscal Year Ended September 30, 2024
File No. 001-37619
Dear Stephen Lemieux:
            We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io